DPP4 and obesity disorder: The substantial body of preclinical evidence in genetic mouse models linking cell-specific actions of DPP4 with insulin resistance, obesity, and NAFLD requires further confirmation and mechanistic studies in patient populations and human model systems to confirm its role as a biomarker or causal agent in disease progression.